Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13).
Antinuclear antibodies
COVID-19
Malignancy
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
11
01
2023
accepted:
30
01
2023
pubmed:
5
2
2023
medline:
23
3
2023
entrez:
4
2
2023
Statut:
ppublish
Résumé
A high prevalence of antinuclear antibodies (ANA) in COVID-19 has been insinuated, but the nature of the target antigens is poorly understood. We studied ANA by indirect immunofluorescence in 229 individuals with COVID-19. The target antigens of high titer ANA (≥1:320) were determined by immunoprecipitation (IP) combined with liquid-chromatography-mass spectrometry (MS). High titer ANA (≥1:320) were found in 14 (6%) of the individuals with COVID-19. Of the 14 COVID-19 cases with high titer ANA, 6 had an underlying autoimmune disease and 5 a malignancy. IP-MS revealed known target antigens associated with autoimmune disease as well as novel autoantigens, including CDK9 (in systemic sclerosis) and RNF20, RCC1 and TRIP13 (in malignancy). The novel autoantigens were confirmed by IP-Western blotting. In conclusion, in depth analysis of the targets of high titer ANA revealed novel autoantigens in systemic sclerosis and in malignant disease.
Identifiants
pubmed: 36738952
pii: S1568-9972(23)00022-8
doi: 10.1016/j.autrev.2023.103288
pmc: PMC9893804
pii:
doi:
Substances chimiques
Autoantibodies
0
Antibodies, Antinuclear
0
Autoantigens
0
CDK9 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 9
EC 2.7.11.22
RCC1 protein, human
0
Nuclear Proteins
0
Cell Cycle Proteins
0
Guanine Nucleotide Exchange Factors
0
TRIP13 protein, human
EC 3.6.4.-
ATPases Associated with Diverse Cellular Activities
EC 3.6.4.-
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
103288Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest XB was part of a scientific advisory committee for Werfen and Thermo Fisher Scientific, and received speaker's fees from Werfen and Thermo Fisher Scientific. The above-mentioned interests were outside the scope of the current work. JBV, LB, GW, SW, GF, NG, SC, HW, PV, RD did not declare any relevant competing interests.